Helping You Build Wealth With Honest Research
Since 1996. Read On...

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GLAND PHARMA Gains 4%; BSE HEALTHCARE Index Up 0.8%
Tue, 6 Aug 10:46

GLAND PHARMA Gains 4%; BSE HEALTHCARE Index Up 0.8%Image source: Ivcandy/www.istockphoto.com

GLAND PHARMA share price has zoomed 4% and is presently trading at Rs 2,191.4.

Meanwhile, the BSE HEALTHCARE index is at 40,404.1 (up 0.8%).

Among the top gainers in the BSE HEALTHCARE index today are ERIS LIFESCIENCES (up 3.1%) and ASTRAZENECA PHARMA (up 3.1%).

FORTIS HEALTHCARE (down 1.2%) and SUN PHARMA ADV. RES. (down 1.0%) are among the top losers today.

Over the last one year, GLAND PHARMA has moved up from Rs 1,288.2 to Rs 2,191.4, registering a gain of Rs 903.3 (up 70.1%).

On the other hand, the BSE HEALTHCARE index has moved up from 27,485.7 to 40,404.1, registering a gain of 47.0% during the last 12 months.

The top gainers among the BSE HEALTHCARE index stocks during this same period were Jubilant Pharmova (up 127.3%), GRANULES INDIA (up 102.7%) and SUVEN PHARMACEUTICALS (up 102.1%).

Must See: These Segments are Witnessing Incredible Growth with Modi's Push

What About the Benchmark Indices?

The BSE Sensex is at 79,156.7 (up 0.5%).

The top gainers among the BSE Sensex today are Tech Mahindra (up 2.1%) and JSW Steel (up 1.8%). The most traded stocks in the BSE Sensex are Tata Steel and Tata Motors.

In the meantime, NSE Nifty is at 24,155.9 (up 0.4%). Tech Mahindra and Grasim Industries are among the top gainers in NSE NIFTY.

Over the last 12 months, the BSE Sensex has moved up from 65,782.8 to 79,156.7, registering a gain of 13,373.9 points (up 20.3%).

GLAND PHARMA Financial Update...

GLAND PHARMA net profit grew 144.6% YoY to Rs 1,924 million for the quarter ended March 2024, compared to a profit of Rs 787 million a year ago. Net sales rose 95.9% to Rs 15,375 million during the period as against Rs 7,850 million in January-March 2023.

For the year ended March 2023, GLAND PHARMA reported 35.5% decrease in net profit to Rs 7,810 million compared to net profit of Rs 12,117 million during FY22. Revenue of the company fell 17.6% to Rs 36,246 million during FY23.

The current Price to earnings ratio of GLAND PHARMA, based on rolling 12 month earnings, stands at 46.7.


Equitymaster requests your view! Post a comment on "GLAND PHARMA Gains 4%; BSE HEALTHCARE Index Up 0.8%". Click here!